Synthetic Lethal Screen Identifies NF-κB as a Target for Combination Therapy with Topotecan for patients with Neuroblastoma

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Tsang, Patricia S ^a   Cheuk, Adam T ^a   Chen, Qing Rong ^a   Song, Young K ^a   Badgett, Thomas C ^a   Wei, Jun S ^a   Khan, Javed ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CASPASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NSC 676914; SMALL INTERFERING RNA; TOPOTECAN; UNCLASSIFIED DRUG; BORONIC ACID DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIRC4 GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CTSD GENE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; GENE TARGETING; GENETIC IDENTIFICATION; GENETIC SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MICROARRAY ANALYSIS; MONOTHERAPY; MOUSE; NEUROBLASTOMA; NFKB1 GENE; NONHUMAN; NOS2A GENE; ONCOGENE; RIPK1 GENE; TGFB1 GENE; TNFRSF10A GENE; TNFRSF25 GENE; TNFRSF8 GENE; TREATMENT RESPONSE; ANIMAL; APOPTOSIS; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; MOUSE MUTANT; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; MICE; MICE, SCID; MICROARRAY ANALYSIS; NEUROBLASTOMA; NF-KAPPA B; PYRAZINES; RNA, SMALL INTERFERING; TOPOISOMERASE I INHIBITORS; TOPOTECAN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862803693     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-101     Document Type: Article

References (40)

1. Brodeur GM, Maris JM. Principles and practice of pediatric oncology 2006, 933-970. Philadelphia: J B Lippincott Company, 5.
2. Cecchetto G, et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005, 23(33):8483-8489. 10.1200/JCO.2005.02.4661, 16293878.
3. Maris JM, et al. Neuroblastoma. Lancet 2007, 369(9579):2106-2120. 10.1016/S0140-6736(07)60983-0, 17586306.
4. Gheeya JS, et al. Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma. Cancer Biol Ther 2009, 8(24):2386-2395. 10.4161/cbt.8.24.10184, 2829338, 19946221.
5. Matthay KK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999, 341(16):1165-1173. 10.1056/NEJM199910143411601, 10519894.
6. Gilman AL, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 2009, 27(1):85-91. 2645092, 19047298.
7. Frost JD, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 1997, 80(2):317-333. 10.1002/(SICI)1097-0142(19970715)80:2<317::AID-CNCR21>3.0.CO;2-W, 9217046.
8. Kushner BH, et al. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol 2000, 35(5):468-474. 10.1002/1096-911X(20001101)35:5<468::AID-MPO5>3.0.CO;2-P, 11070479.
9. Park JR, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol 2011, 29(33):4351-7. 10.1200/JCO.2010.34.3293, 22010014.
10. London WB, et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol 2010, 28(24):3808-15. 10.1200/JCO.2009.27.5016, 2940398, 20660830.
11. Saylors RL, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001, 19(15):3463-3469.
12. Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 1989, 28(11):4629-4638. 10.1021/bi00437a018, 2548584.
13. Armstrong DK, et al. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. Oncologist 2005, 10(9):686-694. 10.1634/theoncologist.10-9-686, 16249347.
14. Fiorica JV. The role of topotecan in the treatment of advanced cervical cancer. Gynecol Oncol 2003, 90(3 Pt 2):S16-S21.
15. Nitschke R, et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 1998, 20(4):315-318. 10.1097/00043426-199807000-00006, 9703003.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
17. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102(43):15545-15550. 10.1073/pnas.0506580102, 1239896, 16199517.
18. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
19. Kang MI, et al. A selective small-molecule nuclear factor-kappaB inhibitor from a high-throughput cell-based assay for "activator protein-1 hits". Mol Cancer Ther 2009, 8(3):571-581. 10.1158/1535-7163.MCT-08-0811, 2813146, 19258426.
20. Demarchi F, Brancolini C. Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies. Drug Resist Updat 2005, 8(6):359-368. 10.1016/j.drup.2005.12.001, 16406769.
21. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008, 269(1):7-17. 10.1016/j.canlet.2008.03.037, 18462867.
22. Li W, et al. New targets of PS-341: BAFF and APRIL. Med Oncol 2010, 27(2):439-445. 10.1007/s12032-009-9230-z, 19452288.
23. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109(Suppl):S81-S96.
24. Small MB, et al. Neoplastic transformation by the human gene N-myc. Mol Cell Biol 1987, 7(5):1638-1645. 365263, 3299052.
25. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441(7092):431-436. 10.1038/nature04870, 16724054.
26. Hideshima T, et al. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res 2006, 12(19):5887-5894. 10.1158/1078-0432.CCR-05-2501, 17020997.
27. Amschler K et A. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways. J Invest Dermatol 2010, 130(4):1073-86. 10.1038/jid.2009.365, 19940859.
28. Sartore-Bianchi A, et al. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 2007, 13(19):5942-5951. 10.1158/1078-0432.CCR-07-0536, 17908991.
29. Nencioni A, et al. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007, 21(1):30-36. 10.1038/sj.leu.2404444, 17096016.
30. Richardson PG, et al. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006, 57:33-47. 10.1146/annurev.med.57.042905.122625, 16409135.
31. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008, 14(6):1649-1657. 10.1158/1078-0432.CCR-07-2218, 18347166.
32. Desai SD, et al. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 1997, 272(39):24159-24164. 10.1074/jbc.272.39.24159, 9305865.
33. Cusack JC, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001, 61(9):3535-3540.
34. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002, 7(1):9-16. 10.1634/theoncologist.7-1-9, 12202783.
35. Brignole C, et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 2006, 98(16):1142-1157. 10.1093/jnci/djj309, 16912267.
36. Bence AK, Adams VR. Clinical Experience With Topotecan. Camptotehcins in cancer therapy 2005, 268. Humana Press Inc, Totowa, NJ, Adams VR, Burke TG.
37. Richardson PG, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009, 144(6):895-903. 10.1111/j.1365-2141.2008.07573.x, 19170677.
38. Moehler T, Goldschmidt H. Therapy of Relapsed and Refractory Multiple Myeloma. Multiple Myeloma 2011, 252. Springer-Verlag Berlin Heidelberg, Germany.
39. Velcade Prescribing information. , http://www.millennium.com/pdf/VelcadePrescribingInformation.pdf
40. Lara PN, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol 2006, 1(9):996-1001. 10.1097/01243894-200611000-00013, 17409985.